Version 1
: Received: 31 October 2023 / Approved: 1 November 2023 / Online: 1 November 2023 (09:21:13 CET)
How to cite:
Kalemera, M.D.; Maertens, G.N. Cell Culture Evaluation Suggests Widely Available HIV Drugs Will Make Effective HTLV-1 Prophylactics. Preprints2023, 2023110045. https://doi.org/10.20944/preprints202311.0045.v1
Kalemera, M.D.; Maertens, G.N. Cell Culture Evaluation Suggests Widely Available HIV Drugs Will Make Effective HTLV-1 Prophylactics. Preprints 2023, 2023110045. https://doi.org/10.20944/preprints202311.0045.v1
Kalemera, M.D.; Maertens, G.N. Cell Culture Evaluation Suggests Widely Available HIV Drugs Will Make Effective HTLV-1 Prophylactics. Preprints2023, 2023110045. https://doi.org/10.20944/preprints202311.0045.v1
APA Style
Kalemera, M.D., & Maertens, G.N. (2023). Cell Culture Evaluation Suggests Widely Available HIV Drugs Will Make Effective HTLV-1 Prophylactics. Preprints. https://doi.org/10.20944/preprints202311.0045.v1
Chicago/Turabian Style
Kalemera, M.D. and Goedele N. Maertens. 2023 "Cell Culture Evaluation Suggests Widely Available HIV Drugs Will Make Effective HTLV-1 Prophylactics" Preprints. https://doi.org/10.20944/preprints202311.0045.v1
Abstract
With an estimated 10 million people infected, the deltaretrovirus human T-cell lymphotropic virus type 1 (HTLV-1) is the second most prevalent pathogenic retrovirus in humans after HIV-1. Like HIV-1, HTLV-1 overwhelmingly persists in a host via a reservoir of latently infected CD4+ T cells. Although most patients are asymptomatic, HTLV-1-associated pathologies are often debilitating and include childhood infective dermatitis and adult T-cell leukaemia/lymphoma (ATLL), which presents in mature adulthood and is associated with poor prognosis with short overall survival despite treatment. Curiously, the strongest indicator for the development of ATLL is the acquisition of HTLV-1 through breastfeeding. There are no therapeutic or preventative regimens for HTLV-1. However, antiretrovirals (ARVs), which target the essential retrovirus enzymes, have been developed for and transformed HIV therapy. Since the architectures of retroviral enzyme active sites are highly conserved, some HIV-specific compounds may be active against HTLV-1. Here, we expand on our work showing that integrase strand transfer inhibitors (INSTIs) and some nucleoside reverse transcriptase inhibitors (NRTIs) block HTLV-1 transmission in cell culture. Specifically, we find that dolutegravir, the INSTI currently recommended as the basis of all new combination antiretroviral therapy prescriptions, and the latest prodrug formulation of the NRTI tenofovir, tenofovir alafenamide, also potently inhibit HTLV-1 infection in cell culture. Our results, if replicated in a clinical setting, could see transmission rates of HTLV-1 and future caseloads of HTLV-1-associated pathologies like ATLL dramatically cut via the simple redistribution of already widely available HIV pills to HTLV-1 endemic areas. Considering our findings with the old medical saying ‘it’s better to prevent than cure’, we highly recommend the inclusion of INSTIs and tenofovir prodrugs in upcoming HTLV-1 clinical trials as potential prophylactics.
Medicine and Pharmacology, Medicine and Pharmacology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
